Bolus injectors also referred as patch
pumps are class of medical devices for subcutaneous self administration
of biologics. Bolus injectors deliver a standardized volume of drug into
subcutaneous tissue over a specified period of time. These injectors
are typically attached to the patient’s body for a few minutes to a few
hours while it delivers the drug into the body. Drug delivery with bolus
injectors also enables additional treatment advances by making it
convenient, safe, and cost effective delivery of many marketed biologics
and biosimilars products.
Bolus injectors market is expected to
grow immensely in the coming years, as the delivery of healthcare
services shifting its paradigm from clinical settings such as hospitals
and private nursing care to the home. The primary driver of the bolus
injectors market is the large number of biologics currently under
development. As per clinical tests database of the National Institutes
of Health, currently more than 800 biological are in the clinical trials
for hundreds of diseases, including autoimmune disorders, cancer and
many more. Biosimilars and biological are often viscous and require
precise training to administer, which often necessitates a patient visit
to a hospital, outpatient clinic, or specialty pharmacy solely for drug
therapy. Bolus injectors have capability to deliver these complex
biologics in a large volume subcutaneously in a simple, reliable, and
inexpensive manner, thus fulfill the unmet need of future drug
development. In addition, other drivers for adoption of the new bolus
injectors include increased patient comfort for greater compliance,
lower healthcare costs by moving therapy from office and healthcare
professional to home and new safety and needle-stick standards. Many of
the established and emerging medical devices companies such as Becton
Dickinson and Ratio Drug Delivery are investing huge amount of time and
resources to boost patient compliance of these injectors. However,
development complexity, stringent regulatory framework and reimbursement
restrictions may slow down the growth of this market.
The global bolus market is segmented by
three criteria: mode of operation, application and geography. The mode
of operation of bolus injectors is further classified into mechanical,
electronic, hydrogel and hydraulic. The electronic injectors held the
largest bolus injector market share in 2013. The prominent applications
for bolus injectors are cancer, autoimmune diseases, blood disorders,
inflammatory diseases and genetic disorders.
Based on geography, the bolus injectors
market has been analyzed as North America, Asia-Pacific, Europe, and the
Rest of the World (RoW). North America and Europe held the largest
shares in terms of market revenue of the global bolus injectors market
in 2013. The primary reasons for North America and Europe holding the
leading positions in the global bolus injector market are high adoption
rate of these devices in clinical and non clinical settings and
increasing demand for needle free injectors and auto-injectors in these
regions. Asia-Pacific is expected to witness highest growth rate during
the forecast period from 2014 to 2020. A number of factors such as
increasing prevalence of critically ill conditions such as autoimmune
diseases and cancer, growing elderly population, increasing focus on
research and development would be fuelling the growth of bolus injector
market in Asia-Pacific in coming years. According to the Department of
Economic and Social Affairs, United Nations, 23 million individuals aged
80 years or over were living in China in 2013. The Department of
Economic and Social Affairs further states that nearly 10 million and 9
million individuals aged 80 years or over were living in India and
Japan, respectively in 2013.
Some of the major players in bolus
injector market include F. Hoffmann-La Roche AG, BD Medical, West
Pharmaceutical Services, Inc., Unilife Corporation, SteadyMed
Therapeutics, Sensile Medical AG, Ratio, Inc., and Valeritas, Inc.
No comments:
Post a Comment